scholarly journals Beta-blockers in heart failure patients with severe chronic kidney disease—time for a randomized controlled trial?

2019 ◽  
Vol 35 (5) ◽  
pp. 728-731 ◽  
Author(s):  
Rajiv Agarwal ◽  
Patrick Rossignol
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Randomized Controlled Trial ◽  
Kidney Disease ◽  
Beta Blockers ◽  
Controlled Trial ◽  
Heart Failure Patients ◽  
Randomized Controlled ◽  
Severe Chronic Kidney Disease

scholarly journals Home‐based aerobic exercise and resistance training for severe chronic kidney disease: a randomized controlled trial

2021 ◽  
Author(s):  
Kiyotaka Uchiyama ◽  
Keika Adachi ◽  
Kaori Muraoka ◽  
Takashin Nakayama ◽  
Takuma Oshida ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Randomized Controlled Trial ◽  
Resistance Training ◽  
Kidney Disease ◽  
Aerobic Exercise ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Home Based ◽  
Severe Chronic Kidney Disease

A PILOT STUDY: PLASMA GALECTIN-3 LEVEL IN HEART FAILURE PATIENTS

2017 ◽  
pp. 101-106
Author(s):  
Thi Thanh Hien Bui ◽  
Hieu Nhan Dinh ◽  
Anh Tien Hoang
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Acute Coronary Syndrome ◽  
Kidney Disease ◽  
Heart Failure Patients ◽  
Coronary Syndrome ◽  
Nyha Classification ◽  
Galectin 3 ◽  
Severe Chronic Kidney Disease ◽  
Esc Guidelines

Background: Despite of considerable advances in its diagnosis and management, heart failure remains an unsettled problem and life threatening. Heart failure with a growing prevalence represents a burden to healthcare system, responsible for deterioration of patient’s daily activities. Galectin-3 is a new cardiac biomarker in prognosis for heart failure. Serum galectin-3 has some relation to heart failure NYHA classification, acute coronary syndrome and clinical outcome. Level of serum galectin-3 give information for prognosis and help risk stratifications in patient with heart failure, so intensive therapeutics can be approached to patients with high risk. Objective: To examine plasma galectin-3 level in hospitalized heart failure patients, investigate the relationship between galectin-3 level with associated diseases, clinical conditions and disease progression in hospital. Methodology: Cross sectional study. Result: 20 patients with severe heart failure as NYHA classification were diagnosed by The ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2012) and performed blood test for serum galectin-3 level. Increasing of serum galectin-3 level have seen in all patients, mean value is 36.5 (13.7 – 74.0), especially high level in patient with acute coronary syndrome and patients with severe chronic kidney disease. There are five patients dead. Conclusion: Serum galectin-3 level increase in patients with heart failure and has some relation to NYHA classification, acute coronary syndrome. However, level of serum galectin-3 can be affected by severe chronic kidney disease, more research is needed on this aspect Key words: Serum galectin-3, heart failure, ESC Guidelines, NYHA

scholarly journals HIGH ON-TREATMENT PLATELET REACTIVITY WITH CLOPIDOGREL VS TICAGRELOR IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE - A RANDOMIZED CONTROLLED TRIAL

2021 ◽  
Vol 77 (18) ◽  
pp. 101
Author(s):  
Andre Franci ◽  
Carlos Barbosa ◽  
Talia Dalcoquio ◽  
Paulo Genestreti ◽  
Rocío Salsoso ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Randomized Controlled Trial ◽  
Kidney Disease ◽  
Platelet Reactivity ◽  
Controlled Trial ◽  
Randomized Controlled

Dyslipidemia in chronic kidney disease: randomized controlled trial of colestilan versus simvastatin in dialysis patients

2014 ◽  
Vol 82 (09) ◽  
pp. 163-172 ◽  
Author(s):  
Chistoph Wanner ◽  
Winfried März ◽  
Andrei Varushchanka ◽  
Natallia Apanasovich ◽  
Nickolay Dosta ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Randomized Controlled Trial ◽  
Kidney Disease ◽  
Controlled Trial ◽  
Dialysis Patients ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document